News about "Sanofi"

Sanofi and Cheplapharm Announce Strategic Partnership for 20 Mature Medicines and Three Sites

Sanofi and Cheplapharm plan to transfer 20 mature medicines and three manufacturing sites to Cheplapharm, with Sanofi set to receive a 26.4 percent equity stake.

Sanofi | 16/09/2026 | By News Bureau

European Commission Expands Sanofi's MenQuadfi Approval to Include Infants from Six Weeks of Age

The European Commission has approved an expanded indication for Sanofi's MenQuadfi vaccine, allowing immunisation of infants from six weeks of age against invasive meningococcal disease caused by serogroups A, C, W and Y.

Sanofi | 05/08/2026 | By News Bureau

EU Approves Sanofi's MenQuadfi for Invasive Meningococcal Disease

Sanofi's MenQuadfi has received European Union (EU) approval for infants from 6 weeks of age, expanding protection against invasive meningococcal disease.

Sanofi | 04/08/2026 | By News Bureau

Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.

Sanofi | 27/07/2026 | By News Bureau |  108

Sanofi Reshapes Executive Committee to Drive Next Phase of Growth

Sanofi has revamped its Executive Committee with a focused leadership team to drive strategic growth, accelerate innovation, and prepare for its next chapter.

Sanofi | 23/07/2026 | By News Bureau |  150

Sanofi's Nexviazyme Meets Primary Goal in Phase 3 Study for Infantile-Onset Pompe Disease

Sanofi's Phase 3 Baby-COMET study showed Nexviazyme improved ventilator-free survival in infants with infantile-onset Pompe disease, supporting plans for a US regulatory filing to expand the therapy's approved indication.

Sanofi | 01/07/2026 | By News Bureau |  141

EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis

The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.

Sanofi | 25/06/2026 | By News Bureau |  167

Japan Approves Sanofi's Wayrilz for Immune Thrombocytopenia

Sanofi’s Wayrilz has been approved in Japan for the treatment of immune thrombocytopenia (ITP). The BTK inhibitor works through multi-immune modulation to address the underlying causes of the disease.

Sanofi | 24/06/2026 | By News Bureau

Sanofi Names Paulo Fontoura to Lead Global R&D Operations

Sanofi has appointed Paulo Fontoura as Global Head of Research and Development (R&D). Based in Paris, he will join the Executive Committee and report directly to CEO Belén Garijo.

Sanofi | 23/06/2026 | By News Bureau |  204

EU Approves Sanofi's Sarclisa SC as First On-Body Injector Cancer Therapy

Sanofi’s Sarclisa subcutaneous has received EU approval as the first anticancer therapy delivered via an On-Body Injector (OBI). Administered through the CirCLIQ OBI, the treatment offers flexible home or outpatient use for multiple myeloma patients while maintaining efficacy across all approved Sarclisa indications and combinations.

Sanofi | 09/06/2026 | By News Bureau |  111